Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02507323
Other study ID # 34665: Ticagrelor v Prasugrel
Secondary ID
Status Withdrawn
Phase Phase 2
First received July 17, 2015
Last updated May 3, 2016
Start date February 2016
Est. completion date November 2017

Study information

Verified date May 2016
Source Baylor College of Medicine
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study has been designed as a randomized, double-blind trial to provide definitive evidence on the effects of ticagrelor and prasugrel on myocardial salvage in patients with anterior ST Segment Elevation Myocardial Infarction (STEMI) undergoing primary Percutaneous Coronary Intervention (PCI). This study will also measure the effects of ticagrelor vs. prasugrel on secondary endpoints listed above. This study design aims to test the hypothesis that ticagrelor will reduce myocardial infarct size as a proportion of the ischemic area at risk when compared to prasugrel.


Description:

Subjects and research staff (including the Magnetic Resonance Imaging (MRI) readers and interventional cardiologists) will not know what active treatment study drug the subjects are receiving.

Study Arm 1: Ticagrelor (180 mg loading dose, followed by 90 mg twice a day) PO plus matching placebo

Study Arm 2: Prasugrel (60 mg loading dose followed by 5 or 10 mg once per day based on weight) PO plus matching placebo

Additional study drug: Aspirin (81mg per day)

Participation in this study will be about 90 days and includes 4 study visits (other than your hospital stay) and 3 telephone calls.

ENROLLMENT PROCEDURES:

The following procedures are to be completed after informed consent has been obtained:

- Informed Consent Form signed

- Medical history

- Vital signs (eg, blood pressure, heart rate, respiration rate, temperature)

- Review for Adverse Events (AEs) and Serious Adverse Events (SAEs) (only AEs possibly related to study procedures and SAEs are collected)

- Documentation of concomitant medications

- Physical exam

- Body height

- Body weight

- 12-lead Electrocardiogram (ECG)

- Angiographic and Percutaneous Coronary Intervention (PCI) data

- Randomization of treatment assignment

- Investigational product dispensing (on Day 0 and during hospital stay) - Loading dose on Day 0 - 3 day investigational product dosing while in the hospital - 30 day supply dispensing of investigational product on Day 3 for subject to take home

- Local laboratory Assessments: - Blood draw for Creatine Kinase-MB (CK-MB) and troponin I - Blood pregnancy (females of childbearing potential only)

FOLLOW UP PROCEDURES:

Day 5

- Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature)

- Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected)

- Cardiac MRI

- Left Ventricular Ejection Fraction (LVEF), Left Ventricular End-Diastolic Volume (LVEDV), Left Ventricular End-Systolic Volume (LVESV) calculations

- Serum creatinine, Complete Blood Count (CBC)

- Documentation of concomitant medications and investigational product compliance

Day 30 (+/- 1 day), Day 60 (+/- 2 days)

- Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature)

- Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected)

- LVEF, LVEDV, LVESV calculations

- Serum creatinine, CBC

- Documentation of concomitant medications and investigational product compliance

- Investigational Product Dispensing

Day 14, Day 44, Day 74 (+/- 2 days):

Phone calls will be performed to ensure drug compliance, review concomitant medications and review any events. On Day 74, study staff will confirm whether or not the subject has seen their regular cardiologist. Subject will be instructed to bring this information with them at the Day 90 visit so that their cardiologist can be told what arm they participated in for continuation of care and medication therapy.

Day 90 or Termination/End of Study (+/- 2 days) :

- Vital signs (eg, sitting blood pressure, heart rate, respiration rate, temperature)

- Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected)

- Cardiac MRI

- LVEF, LVEDV, LVESV calculations

- Serum creatinine, CBC

- Documentation of concomitant medications and investigational product compliance

- If available and subject consents, subject's cardiologist will be informed what arm of the study they participated in for continuation of care and medication therapy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Informed consent: Signed informed consent prior to any study specific procedures

2. Age: Male and females aged 18 years and older

3. Onset: Presenting to emergency room or cardiac catheterization laboratory within 6 hours of onset of myocardial infarction symptoms

4. Continuing to have ongoing myocardial infarction symptoms

5. EKG findings: ST elevation on ECG with positive T waves in the precordial leads, suggestive of anterior STEMI

6. Triaged for emergency cardiac catheterization (primary PCI protocol)

7. Agree to use an effective contraceptive method beginning at the signing of the informed consent and for at least 30 days after the last dose of study drug. The definition of an effective method of contraception will be based on the judgment of the investigator.

Exclusion Criteria:

1. Prior myocardial infarction

2. Contraindication to ticagrelor and/or prasugrel

3. Contraindication to gadolinium

4. Contraindication to aspirin

5. Treatment with fibrinolytic therapy for the index STEMI

6. High risk of bleeding

7. Presenting with cardiogenic shock

8. Infarction due to stent thrombosis

9. History of a previous coronary artery bypass graft (CABG)

10. Known renal insufficiency (acute kidney injury or Glomerular Filtration Rate < 40 mL/min/1.73 m2).

11. Moderate or severe hepatic impairment

12. Inability to undergo cardiac MRI

13. Indication for aspirin >162 mg/d

14. Indication for Nonsteroidal Anti-Inflammatory Drugs or COX2 inhibitors

15. Pregnant

16. Breast feeding

17. History of intracranial hemorrhage

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
ticagrelor
A platelet aggregation inhibitor
prasugrel
a thienopyridine class inhibitor of platelet activation and aggregation
Placebo
placebo

Locations

Country Name City State
United States Baylor-St. Lukes Medical Center Houston Texas
United States Houston Methodist Hospital Houston Texas
United States Memorial Hermann Hospital Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Yochai Birnbaum AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy as measured by infarct size on all randomized patients. up to Day 90 No
Secondary Safety as measured by incidences of treatment emergent adverse events, serious adverse events, treatment-related adverse events and adverse events leading to stop of drug for 90 day major adverse cardiac events and bleeding complications 90 days No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A